PATENT CLAIM ANALYSIS

Application Number: 16106104
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "301000"]

Abstract:
The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

Claim (Index 18):
The method of  claim 16 , wherein the disorder mediated by SGLT activity is selected from the group consisting of impaired glucose tolerance, impaired fasting glucose, Type II Diabetes Mellitus, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, hypertension, heart disease, ischemia, stroke, non-alcoholic steatohepatitus (NASH), non-alcoholic fatty liver disease (NAFLD), liver fibrosis, cataracts, polycystic ovarian syndrome, irritable bowel disorder, inflammation, prostate cancer and pancreatic cancer.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 96.0
- Lexical Diversity: 1.08108
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14593071', '16059072', '16059074', '13634597', '14122836']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8364670832729172
- 35 USC 102 Novelty (BERT): 0.5292580148203735
- Combined Prediction Score: 0.8057461764276628
- Mean Citation Score: 351.143048
- Max Citation Score: 357.37866
- Similarity Product: 236.0987662144876

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test